Biomarkers for Lupus Nephritis: A Critical Appraisal

Abstract

Kidney disease is one of the most serious manifestations of systemic lupus erythematosus (SLE). Despite the improvement in the medical care of SLE in the past two decades, the prognosis of lupus nephritis remains unsatisfactory. Besides exploring more effective but less toxic treatment modalities that will further improve the remission rate, early detection and treatment of renal activity may spare patients from intensive immunosuppressive therapies and reduce renal damage. Conventional clinical parameters such as creatinine clearance, proteinuria, urine sediments, anti-dsDNA, and complement levels are not sensitive or specific enough for detecting ongoing disease activity in the lupus kidneys and early relapse of nephritis. Thus, novel biomarkers are necessary to enhance the diagnostic accuracy and sensitivity of lupus renal disease, prognostic stratification, monitoring of treatment response, and detection of early renal flares. This paper reviews promising biomarkers that have recently been evaluated in longitudinal studies of lupus nephritis.

Cited by papers we hold 4

• Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis · 2020
  Not checked
• Value of monitoring urine ammonia at time of biopsy in patients with lupus nephritis · 2020
  Not checked
• Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome · 2017
  No notice
• IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment · 2015
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.